OPKO Health, Inc. (OPK)
|Net Income (ttm)||70.91M|
|Day's Range||3.63 - 3.70|
|52-Week Range||3.02 - 6.27|
|Price Target||6.60 (+78.9%)|
|Est. Earnings Date||Oct 28, 2021|
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers ... [Read more...]
Financial PerformanceFinancial Statements
According to 5 analysts, the average rating for OPKO Health stock is "Buy." The 12-month stock price forecast is 6.60, which is an increase of 78.86% from the latest price.
On Monday, Opko Health Inc. (NASDAQ:OPK) shares edged slightly higher after Jefferies and Piper Sandler analysts issued upbeat statements following Friday's decline. The OPK stock price slipped more tha...
The FDA extends the PDUFA action date for OPKO (OPK)/Pfizer's BLA for somatrogon to treat pediatric patients with growth hormone deficiency. The review period has been further extended by three months.
Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Gr...
NEW YORK and MIAMI, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has extended the review...
GAITHERSBURG, Md., Sept. 21, 2021 /PRNewswire/ -- GeneDx, Inc., a leader in genomic analysis, a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today ann...
OPKO Health (OPK) forms a new JV with LeaderMed to establish a presence in China through expansion of the global availability of two of the former's long-acting development products.
LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntomodulin and Factor VIIa-CTP in ...
SHANGHAI and MIAMI, Sept. 14, 2021 (GLOBE NEWSWIRE) -- LeaderMed Health Group Limited, a pharmaceutical development company with operations based in Asia, and OPKO Health, Inc. (NASDAQ: OPK), a diversif...
Which Reddit penny stocks are on your watchlist right now? The post Best Reddit Penny Stocks To Buy Now?
OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 Outpati...
MIAMI, Aug. 30, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces the completion of enrollment in its Phase 2 trial with RAYALDEE® as a treatment for mild-to-moderate COVID-19. The U.S....
MIAMI, Aug. 30, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in two upcoming virtual investor conferences.
Rite Aid, in Partnership with the U.S. Department of Health and Human Services, BioReference Laboratories and New Yor...
CAMP HILL, Pa.--(BUSINESS WIRE)--Rite Aid (NYSE: RAD) and the U.S. Department of Health and Human Services (HHS), together with BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), anno...
OPKO Health's (OPK) BioReference's acquisition to expand its NIPS offerings and thereby enhance prenatal screening.
ELMWOOD PARK, N.J., Aug. 16, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the acquisition of the U.S. Ariosa centralized laboratory prenatal...
Are these penny stocks worth watching with the stock market down today? The post Top Penny Stocks to Buy?
Are these biotech penny stocks worth investing in or not? The post 3 Hot Biotech Penny Stocks to Watch With High Volume in 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | Penny...
The coronavirus stock didn't impress with its Q2 results.
OPKO Health's (OPK) second-quarter results benefit from strength in both its reportable segments.
OPKO Health (OPK) delivered earnings and revenue surprises of -250.00% and -3.31%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today
OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MIAMI, July 20, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended June 30, 2021, as well as discuss financial guidance, ...
With Reddit's regular targets finally dropping, these stocks could be the next target for another crazy wave of Reddit Penny Stocks. The post 7 Reddit Penny Stocks About to Explode appeared first on Inv...
The market's pessimism about these diagnostics stocks appeared unrelated to company-specific news.
OPKO Health's (OPK) latest licensing agreement is expected to advance the development and commercialization of potential disease-modifying therapeutics, especially for Dravet syndrome.
OPKO Health Inc (NASDAQ: OPK) has entered into an exclusive worldwide agreement with privately-held CAMP4 Therapeutics Corporation (CAMP4) to develop, manufacture, and commercialize therapeutics utilizi...
MIAMI, July 12, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced it has entered into an exclusive worldwide agreement with privately held CAMP4 Therapeutics Corporation (CAMP4) f...